Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug candidates, today announced that its common shares will...
Company is committed to evaluating use of the broad-spectrum antiviral in the early treatment setting of COVID-19 to shorten the time to clinical recovery in adult patients with mild to moderate...
Appili Therapeutics Inc. (TSXV: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug candidates, today announced that its leadership team will...
Appili Therapeutics Inc. (TSXV: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug candidates, today announced its financial and operational...
Appili Therapeutics Inc. (TSXV: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug candidates, today announced that its common shares listed...
U.S. expansion of antiviral outbreak control trial in long-term care facilities Favipiravir already approved in India and Russia for emergency use against COVID-19 and as a pandemic influenza...
Site screening is required in advance of potential outbreaks in Ontario long-term care centers Only trial in the world investigating use of favipiravir as preventative measure against COVID-19...
Company well-capitalized, reporting record level of capital support with over $27M CAN in equity financings Pipeline portfolio strengthened with initiation of unique COVID-19 clinical study...
Appili Therapeutics Inc. (TSXV: APLI; OTCQX: APLIF) (the “Company” or “Appili”) is pleased to announce today that its common shares began trading on the OTCQX Best Market®. The OTCQX Market...
L'OCRCVM permet la reprise de la négociation - APLI Canada NewsWire VANCOUVER, BC, le 4 juin 2020 VANCOUVER, BC, le 4 juin 2020 /CNW/ - Reprise des négociations pour : Société : Appili...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 1.09 | 1.09 | 1.09 | 0 | 0 | CS |
4 | 0 | 0 | 1.09 | 1.09 | 1.09 | 0 | 0 | CS |
12 | 0 | 0 | 1.09 | 1.09 | 1.09 | 0 | 0 | CS |
26 | 0 | 0 | 1.09 | 1.09 | 1.09 | 0 | 0 | CS |
52 | 0 | 0 | 1.09 | 1.09 | 1.09 | 0 | 0 | CS |
156 | 0 | 0 | 1.09 | 1.09 | 1.09 | 0 | 0 | CS |
260 | 0.44 | 67.6923076923 | 0.65 | 1.89 | 0.5 | 17838 | 1.17755181 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.